State of Wisconsin Investment Board Sells 2,605 Shares of Stryker Corporation $SYK

State of Wisconsin Investment Board trimmed its position in Stryker Corporation (NYSE:SYK) by 1.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 185,388 shares of the medical technology company’s stock after selling 2,605 shares during the period. State of Wisconsin Investment Board’s holdings in Stryker were worth $65,158,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. VanderPol Investments L.L.C. lifted its stake in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the last quarter. KCM Investment Advisors LLC lifted its stake in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares during the last quarter. Rossby Financial LCC lifted its stake in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after acquiring an additional 28 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its stake in shares of Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after acquiring an additional 29 shares during the last quarter. Finally, Tcfg Wealth Management LLC increased its holdings in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 0.9%

Shares of NYSE:SYK opened at $310.71 on Wednesday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s 50-day moving average is $315.51 and its 200-day moving average is $342.88. The company has a market capitalization of $119.11 billion, a price-to-earnings ratio of 35.96, a P/E/G ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SYK. BTIG Research decreased their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Evercore set a $355.00 price objective on Stryker in a report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.